SCHEMBL1492325

SCHEMBL1492325

CCOC(=O)c1[nH]ccc1NC(C)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.50
SMN1; SMN2 Q16637 3/20 0.46
KMT2A Q03164 3/20 0.46
ALDH1A1 P00352 6/20 0.45
HPGD P15428 4/20 0.45
HSD17B10 Q99714 1/20 0.45
MAPT P10636 1/20 0.45
LMNA P02545 4/20 0.45
GALR2 O43603 1/20 0.45
MITF O75030 1/20 0.45
POLB P06746 1/20 0.45
HSP90AA1 P07900 1/20 0.45
XBP1 P17861 1/20 0.45
CCR6 P51684 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
NUDT1 P36639 1/20 0.43
GAA P10253 2/20 0.43
MAPK1 P28482 2/20 0.43
GLA P06280 1/20 0.43
PPARG P37231 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25241521 0.86 KDM4E (0.51) KDM4EKMT2AALDH1A1HPGDHSD17B10
SCHEMBL4200796 0.86 ALDH1A1 (0.45) KDM4ESMN1; SMN2KMT2AALDH1A1HPGD
SCHEMBL2626729 0.83 KMT2A (0.44) KDM4ESMN1; SMN2KMT2AALDH1A1HPGD
SCHEMBL4393322 0.81 KDM4E (0.41) KDM4ESMN1; SMN2KMT2AALDH1A1HPGD
SCHEMBL18557963 0.80 KMT2A (0.43) KDM4ESMN1; SMN2KMT2AALDH1A1HPGD
SCHEMBL25892876 0.80 KMT2A (0.43) KDM4ESMN1; SMN2KMT2AALDH1A1HPGD
SCHEMBL24958271 0.79 SMN1; SMN2 (0.44) KDM4ESMN1; SMN2KMT2AALDH1A1HPGD
Hydrochloric Acid SCHEMBL15741118 0.78 ALDH1A1 (0.39) KDM4ESMN1; SMN2KMT2AALDH1A1HPGD
SCHEMBL1536614 0.78 ALDH1A1 (0.44) KDM4ESMN1; SMN2KMT2AALDH1A1MAPT
SCHEMBL1536764 0.78 LMNA (0.44) KDM4ESMN1; SMN2KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162890-B2 Heteroaromatic NMDA receptor modulators and uses thereof NOVARTIS AG (CH) 2024-12-10 US disclosed
US-20230023543-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2023-01-26 US disclosed
US-20230023543-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2023-01-26 US disclosed
CN-109071446-B Organic reaction in aqueous solution in the presence of hydroxyalkyl (alkyl) cellulose or alkylcellulose 艾伯维德国有限责任两合公司 2022-06-21 CN disclosed
US-11312668-B2 Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose ABBVIE INC. (US) 2022-04-26 US disclosed
US-11312668-B2 Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose ABBVIE INC. (US) 2022-04-26 US disclosed
US-11236104-B2 Heteroaromatic NMDA receptor modulators and uses thereof CADENT THERAPEUTICS, INC. (US) 2022-02-01 US disclosed
US-11236104-B2 Heteroaromatic NMDA receptor modulators and uses thereof CADENT THERAPEUTICS, INC. (US) 2022-02-01 US disclosed
US-20210107916-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2021-04-15 US disclosed
US-20210107916-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2021-04-15 US disclosed
EP-2566868-A1 PYRROLO [3, 2 -D]PYRIMIDIN-3 -YL DERIVATIVES USED AS ACTIVATORS OF AMPK GlaxoSmithKline LLC (US) 2013-03-13 EP disclosed
US-20130053407-A1 PYRROLO [3,2-D] PYRIMIDIN-3-YL DERIVATIVES USED AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2013-02-28 US disclosed
WO-2012119979-A1 1H-PYROLLO[3,2-d]PYRIMIDINEDIONE DERIVATIVES GLAXOSMITHKLINE LLC (US) 2012-09-13 WO disclosed
WO-2012119979-A1 1H-PYROLLO[3,2-d]PYRIMIDINEDIONE DERIVATIVES GLAXOSMITHKLINE LLC (US) 2012-09-13 WO disclosed
EP-2475660-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GlaxoSmithKline LLC (US) 2012-07-18 EP disclosed
US-20120172333-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2012-07-05 US disclosed
US-20120172333-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2012-07-05 US disclosed
WO-2011138307-A1 PYRROLO [3, 2 -D] PYRIMIDIN-3 -YL DERIVATIVES USED AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2011-11-10 WO disclosed
WO-2011029855-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2011-03-17 WO disclosed
WO-2011029855-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2011-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236104-B2 Heteroaromatic NMDA receptor modulators and uses thereof GRIN2C, GRIN2A, GRIN1 KDM4E 1570/4885SMN1; SMN2 4683/4885KMT2A 573/4885
US-12162890-B2 Heteroaromatic NMDA receptor modulators and uses thereof GRIN2C, GRIN2A, GRIN1 KDM4E 1570/4885SMN1; SMN2 4683/4885KMT2A 573/4885
US-20120172333-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK PRKAB1, PRKAG1, PRKAB2 KDM4E 1540/4885SMN1; SMN2 4359/4885KMT2A 2761/4885
US-11312668-B2 Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose LIPA, ALG1, CEL KDM4E 3907/4885SMN1; SMN2 4687/4885KMT2A 4694/4885
US-20230023543-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN2C, GRIN2A, GRIN1 KDM4E 1570/4885SMN1; SMN2 4683/4885KMT2A 573/4885
US-20210107916-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN2C, GRIN2A, GRIN1 KDM4E 1570/4885SMN1; SMN2 4683/4885KMT2A 573/4885
US-20130053407-A1 PYRROLO [3,2-D] PYRIMIDIN-3-YL DERIVATIVES USED AS ACTIVATORS OF AMPK PRKAG2, PRKAB2, PRKAG3 KDM4E 2191/4885SMN1; SMN2 3679/4885KMT2A 2783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.